Skip to main content
NCD 190.24 · version 1 · Laboratory NCD

NCD 190.24: Digoxin Therapeutic Drug Assay

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.24

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
409 covered ICD-10
233 non-covered

TL;DR

NCD 190.24 sets Medicare's national policy for digoxin therapeutic drug assay under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. Digoxin levels may be performed to monitor drug levels of individuals receiving digoxin therapy because the margin of safety between side effects and toxicity is narrow or because the blood level may not be high enough to achieve the desired clinical effect. As a laboratory NCD it carries a national ICD-10 edit list: 409 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.

Item or service described

A digoxin therapeutic drug assay is useful for diagnosis and prevention of digoxin toxicity, and/or prevention for under dosage of digoxin.

Indications and limitations of coverage

Indications

Digoxin levels may be performed to monitor drug levels of individuals receiving digoxin therapy because the margin of safety between side effects and toxicity is narrow or because the blood level may not be high enough to achieve the desired clinical effect.

Clinical indications may include individuals on digoxin:

• With symptoms, signs or electrocardiogram (ECG) suggestive of digoxin toxicity.

• Taking medications that influence absorption, bioavailability, distribution, and/or elimination of digoxin.

• With impaired renal, hepatic, gastrointestinal, or thyroid function.

• With pH and/or electrolyte abnormalities.

• With unstable cardiovascular status, including myocarditis.

• Requiring monitoring of patient compliance.

Clinical indications may include individuals:

• Suspected of accidental or intended overdose.

• Who have an acceptable cardiac diagnosis (as listed) and for whom an accurate history of use of digoxin is unobtainable.

The value of obtaining regular serum digoxin levels is uncertain, but it may be reasonable to check levels once yearly after a steady state is achieved. In addition, it may be reasonable to check the level if:

• Heart failure status worsens.

• Renal function deteriorates.

• Additional medications are added that could affect the digoxin level.

• Signs or symptoms of toxicity develop.

Steady state will be reached in approximately 1 week in patients with normal renal function, although 2-3 weeks may be needed in patients with renal impairment. After changes in dosages or the addition of a medication that could affect the digoxin level, it is reasonable to check the digoxin level one week after the change or addition. Based on the clinical situation, in cases of digoxin toxicity, testing may need to be done more than once a week.

Digoxin is indicated for the treatment of patients with heart failure due to systolic dysfunction and for reduction of the ventricular response in patients with atrial fibrillation or flutter. Digoxin may also be indicated for the treatment of other supraventricular arrhythmias, particularly in the presence of heart failure.

Limitations

This test is not appropriate for patients on digitoxin or treated with digoxin FAB (fragment antigen binding) antibody.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.24 version 1. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 409 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.24
CodeCode set
80162CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $13.28, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.24 edits, October 2026
CodeCLFS amountWith QWPricing
80162$13.28—national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 409 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.24 (sample)
ICD-10-CMDescriptionEffective
A18.84Tuberculosis of heart2015-10-01
E00.0Congenital iodine-deficiency syndrome, neurological type2015-10-01
E00.1Congenital iodine-deficiency syndrome, myxedematous type2015-10-01
E00.2Congenital iodine-deficiency syndrome, mixed type2015-10-01
E00.9Congenital iodine-deficiency syndrome, unspecified2015-10-01
E01.8Other iodine-deficiency related thyroid disorders and allied conditions2015-10-01
E02Subclinical iodine-deficiency hypothyroidism2015-10-01
E03.0Congenital hypothyroidism with diffuse goiter2015-10-01
E03.1Congenital hypothyroidism without goiter2015-10-01
E03.2Hypothyroidism due to medicaments and other exogenous substances2015-10-01
E03.3Postinfectious hypothyroidism2015-10-01
E03.5Myxedema coma2015-10-01
E03.8Other specified hypothyroidism2015-10-01
E03.9Hypothyroidism, unspecified2015-10-01
E05.00Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm2015-10-01
E05.01Thyrotoxicosis with diffuse goiter with thyrotoxic crisis or storm2015-10-01
E05.10Thyrotoxicosis with toxic single thyroid nodule without thyrotoxic crisis or storm2015-10-01
E05.11Thyrotoxicosis with toxic single thyroid nodule with thyrotoxic crisis or storm2015-10-01
E05.20Thyrotoxicosis with toxic multinodular goiter without thyrotoxic crisis or storm2015-10-01
E05.21Thyrotoxicosis with toxic multinodular goiter with thyrotoxic crisis or storm2015-10-01
E05.30Thyrotoxicosis from ectopic thyroid tissue without thyrotoxic crisis or storm2015-10-01
E05.31Thyrotoxicosis from ectopic thyroid tissue with thyrotoxic crisis or storm2015-10-01
E05.40Thyrotoxicosis factitia without thyrotoxic crisis or storm2015-10-01
E05.41Thyrotoxicosis factitia with thyrotoxic crisis or storm2015-10-01
E05.80Other thyrotoxicosis without thyrotoxic crisis or storm2015-10-01
E05.81Other thyrotoxicosis with thyrotoxic crisis or storm2015-10-01
E05.90Thyrotoxicosis, unspecified without thyrotoxic crisis or storm2015-10-01
E05.91Thyrotoxicosis, unspecified with thyrotoxic crisis or storm2015-10-01
E06.0Acute thyroiditis2015-10-01
E06.1Subacute thyroiditis2015-10-01
E06.2Chronic thyroiditis with transient thyrotoxicosis2015-10-01
E06.3Autoimmune thyroiditis2015-10-01
E06.4Drug-induced thyroiditis2015-10-01
E06.5Other chronic thyroiditis2015-10-01
E06.9Thyroiditis, unspecified2015-10-01
E20.1Pseudohypoparathyroidism2015-10-01
E83.40Disorders of magnesium metabolism, unspecified2015-10-01
E83.41Hypermagnesemia2015-10-01
E83.42Hypomagnesemia2015-10-01
E83.49Other disorders of magnesium metabolism2015-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.24 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 8 codes added and 3 codes removed against January 2026. CMS marked 8 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.

ICD-10-CM codes added to NCD 190.24 in October 2026
ICD-10-CMFY2027 descriptionResult
I42.00Dilated cardiomyopathy, unspecifiedcovered
I42.01Familial-genetic dilated cardiomyopathycovered
I42.09Other dilated cardiomyopathycovered
I42.81Arrhythmogenic cardiomyopathycovered
I42.89Other cardiomyopathies not elsewhere classifiedcovered
I49.81Brugada syndromecovered
I49.82Ventricular bigeminycovered
I49.89Other specified cardiac arrhythmias not elsewhere classifiedcovered
ICD-10-CM codes removed from NCD 190.24 in October 2026
ICD-10-CMDescriptionWasWhy
I42.0Dilated cardiomyopathycovereddeleted from ICD-10-CM; replaced by I42.00, I42.01, I42.09
I42.8Other cardiomyopathiescovereddeleted from ICD-10-CM; replaced by I42.81, I42.89
I49.8Other specified cardiac arrhythmiascovereddeleted from ICD-10-CM; replaced by G90.A, I49.81, I49.82, I49.89

Codes on this NCD's list by release: October 2025: 637 · January 2026: 637 · October 2026: 642. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Revision history

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.24

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.24

What does NCD 190.24 cover?

Digoxin levels may be performed to monitor drug levels of individuals receiving digoxin therapy because the margin of safety between side effects and toxicity is narrow or because the blood level may not be high enough to achieve the desired clinical effect. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.24 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.24?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.24?

The October 2026 laboratory NCD edit list contains 409 ICD-10-CM codes that support digoxin therapeutic drug assay (for example A18.84 Tuberculosis of heart; E00.0 Congenital iodine-deficiency syndrome, neurological type; E00.1 Congenital iodine-deficiency syndrome, myxedematous type) and 233 codes that deny. The list applies to 80162.

How often does the lab NCD code list for 190.24 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.